EcoDrugPlus

Farnesyltransferase, Caax Box, Beta

Ensembl ID : ENSCCRG00000024934
Gene Symbol: FNTB
1 Cross references
201 Possible Orthologues:

Fibroblast Growth Factor Receptor 1a

Ensembl ID : ENSCCRG00000033246
Gene Symbol: FGFR1A
1 Cross references
204 Possible Orthologues:

Fibroblast Growth Factor Receptor 1a

Ensembl ID : ENSCCRG00000005159
Gene Symbol: FGFR1A
1 Cross references
203 Possible Orthologues:

Fibroblast Growth Factor Receptor 1b

Ensembl ID : ENSCCRG00000013460
Gene Symbol: FGFR1B
1 Cross references
144 Possible Orthologues:

Fibroblast Growth Factor Receptor 1b

Ensembl ID : ENSCCRG00000017009
Gene Symbol: FGFR1B
1 Cross references
144 Possible Orthologues:

Fibroblast Growth Factor Receptor 2

Ensembl ID : ENSCCRG00000031692
Gene Symbol: FGFR2
1 Cross references
218 Possible Orthologues:

Fibroblast Growth Factor Receptor 2

Ensembl ID : ENSCCRG00000009600
Gene Symbol: FGFR2
1 Cross references
219 Possible Orthologues:

Fibroblast Growth Factor Receptor 3

Ensembl ID : ENSCCRG00000058736
Gene Symbol: FGFR3
1 Cross references
146 Possible Orthologues:

Fibroblast Growth Factor Receptor 3

Ensembl ID : ENSCCRG00000016440
Gene Symbol: FGFR3
1 Cross references
146 Possible Orthologues:

Fms Related Receptor Tyrosine Kinase 1

Ensembl ID : ENSCCRG00000027874
Gene Symbol: FLT1
1 Cross references
195 Possible Orthologues:

Fms Related Receptor Tyrosine Kinase 1

Ensembl ID : ENSCCRG00000045302
Gene Symbol: FLT1
1 Cross references
196 Possible Orthologues:

Fms Related Receptor Tyrosine Kinase 4

Ensembl ID : ENSCCRG00000044738
Gene Symbol: FLT4
1 Cross references
194 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).